Clinical Trial Update: Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B [Phase 4]

View source ↗

Summary

Phase 4 study of BENEFIX in previously treated patients with Hemophilia B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia B | Phase 4 | Status: COMPLETED